Brian Wong, RAPT Therapeutics president and CEO
RAPT Therapeutics bolsters partner search with PhII data on small molecule-Keytruda combo
RAPT Therapeutics is offering the first look at Phase II data suggesting that adding its small molecule CCR4 antagonist to Keytruda is leading to hoped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.